S. 4109 · 119th Congress · Health
Stem Cell Therapeutic and Research Reauthorization Act of 2026
Reauthorizes stem cell therapeutic and research programs and funding. AI-read
- IntroducedMar 17, 2026 Done
- CommitteeReported Jun 22, 2026 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA).
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. The bill also expands periodic reviews of the state of stem cell science to specifically include a review of the use of high-quality cord blood units and other emergent technologies to develop new therapies for potential inclusion in the program.
Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
Congressional Research Service · summary of “Reported to Senate” version · Jun 22, 2026
Who lobbies on it
2 organizations, more than 73% of Senate bills · 5 filings · Q1 2026–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
College of American Pathologists
3 of 3 quarters
“H.R.8163 - To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program S.4254 - A bill to amend the Public Health Service Act to provide for a health care workforce innovation program. S.4109 - A bill to reauthorize the Stem Cell Therapeutic and Research Act of…”
$689K lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Susan B Anthony List
2 of 3 quarters
“…S.4109 - Stem Cell Therapeutic and Research Reauthorization Act of 2026 S.3799, H.R.3302 - Healthy Start Reauthorization Act of 2026 H.R.8239 - SACRED Act S.4880, H.R.8603 - Dismemberment Abortion Ban Act of 2026 S.4873 - Promoting Human Flourishing in Foreign Assistance Act S.253, H.R.73- Abortion Is Not Health Care…”
$1.1M lobbying spend in 2026 to date, all issuesQ3 2026 filing
Organizations that named S. 4109 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
5 actions · newest first- Jun 22, 2026Placed on Senate Legislative Calendar under General Orders. Calendar No. 443.
- Jun 22, 2026Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.
- Jun 17, 2026Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
- Mar 17, 2026Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S1093)
Show all 5 actionsShow fewer
- Mar 17, 2026Introduced in Senate
What members said about it
-
Key Committee Advances Reed’s Bill to Renew & Improve National Bone Marrow & Cord Blood Programs
In a big step toward enhancing patient access to life-saving bone marrow and cord blood transplants, the Senate Committee on Health, Education, Labor and Pensions (HELP) today unanimously voted to advance U.S Senator Jack Reed’s (D-RI)…
“Thanks to sustained federal investment, advancements in innovative research have been amazing and we want to accelerate that progress by passing this bill and funding these life-saving programs. This bill will help patients and families in their time of need as they face unimaginable circumstances. It provides direct…”
-
Bipartisan Reed-Scott Bill Offers Hope for Life-Saving Research & Life-Enhancing Treatments and Care
In an effort to help thousands of patients suffering from diseases requiring bone marrow and cord blood transplants, U.S Senator Jack Reed (D-RI) today introduced the Stem Cell Therapeutic and Research Reauthorization Act of 2026 (S.4109).
“Ultimately, this is all about helping patients and families in their time of need as they face unimaginable circumstances. It provides direct support to these critical institutions that do incredible research, match donors and patients, help save live lives, and improve health outcomes.”